Oric Pharmaceuticals (ORIC) AI Stock Analysis

• Market Cap: $938.32M
• Dividend Yield: N/A
• Average Volume (3M): 867.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: N/A
• EPS Growth: 7.15%
• Country: US
• Employees: 122
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 85,224,190
• 10 Day Avg. Volume: 580,027
• 30 Day Avg. Volume: 867,958
• PEG Ratio: 2.12
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.99
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 214.01
• Enterprise Value/Gross Profit: 3.40K
• Enterprise Value/Ebitda: -1.63
• 1Y Price Target: $18.00
• Price Target Upside: 62.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 43 Neutral
• Price Target: ―

Oric Pharmaceuticals' overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company's stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.

Positive Factors

Efficacy and Safety

In dose escalation Phase 1b, the '944 combination data showed favorable efficacy and safety compared to Pfizer's mevrometostat.

Financial Position

ORIC announced a concurrent private placement raising $125 million, extending cash runway into the second half of 2027 and through the anticipated primary endpoint readout from the planned Phase 3 trial in mCRPC.

Prostate Cancer Treatment

Solid prostate cancer data with two separate AR inhibitors, along with a clean safety profile, well positions ORIC's drug in the metastatic castration-resistant prostate cancer market.

Negative Factors

Adverse Event Rate

Investors focused on the safety profile with a high treatment-related Grade ≥3 adverse event rate of 49%.

NSCLC Program Neglect

Investors are currently ignoring ORIC's EGFR ex20 NSCLC program.

Oric Pharmaceuticals Business Overview & Revenue Model

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

How the Company Makes Money

Oric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary

Oric Pharmaceuticals shows typical characteristics of a biotechnology firm in the development stage, with no revenue generation, negative profitability metrics, and reliance on equity and financing to fund operations. While the balance sheet demonstrates financial stability through high equity and cash reserves, the lack of revenue and ongoing cash consumption present significant risks.

Income Statement

Oric Pharmaceuticals has consistently reported zero revenue over the years, indicating that the company is still in the development phase typical for biotechnology firms. The persistent net losses and negative EBIT and EBITDA highlight ongoing operational challenges without any revenue to offset costs. This results in minimal profitability and growth metrics.

Balance Sheet

The company maintains a strong equity position with zero total debt, resulting in a favorable debt-to-equity ratio. The high equity ratio indicates financial stability, while the substantial cash reserves suggest good liquidity to support ongoing operations and development activities. However, the continuous net losses may eventually impact equity if no revenue generation occurs.

Cash Flow

Operating cash flows have been consistently negative, reflecting the company's cash consumption due to ongoing operations without revenue inflows. The company has managed to maintain liquidity through financing activities, as seen in positive financing cash flows. However, free cash flow remains negative, highlighting the need for continual financing to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.03M	-966.00K	-897.00K	-970.00K
EBITDA	-126.74M	-109.75M	-91.77M	-77.97M	-74.19M
Net Income	-127.85M	-100.70M	-91.48M	-77.68M	-97.27M
Balance Sheet
Total Assets	274.14M	252.01M	247.18M	298.64M	299.00M
Cash, Cash Equivalents and Short-Term Investments	255.96M	208.19M	206.27M	236.98M	293.60M
Total Debt	3.18M	10.21M	2.66M	1.93M	0.00
Total Liabilities	31.02M	27.92M	24.83M	25.67M	9.22M
Stockholders Equity	243.12M	224.09M	222.35M	272.98M	289.78M
Cash Flow
Free Cash Flow	-113.85M	-86.54M	-77.22M	-60.48M	-45.94M
Operating Cash Flow	-112.66M	-85.69M	-75.14M	-59.54M	-45.27M
Investing Cash Flow	22.14M	-43.40M	-109.25M	158.44M	-215.96M
Financing Cash Flow	126.55M	85.66M	25.62M	49.13M	250.51M

Oric Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 11.06 is above the 20-day moving average (MA) of 10.70, above the 50-day MA of 8.72, and above the 200-day MA of 8.40, indicating a bullish trend. The MACD of 0.62 indicates Positive momentum. The RSI at 63.38 is Neutral, neither overbought nor oversold. The STOCH value of 55.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.

Oric Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUTL	54 Neutral	$641.40M	―	-49.91%	―	-14.16%	25.88%
Sector *	52 Neutral	$7.36B	-0.04	-63.75%	2.59%	16.22%	0.01%
CKPT	45 Neutral	$370.71M	―	-1869.55%	―	-60.19%	56.60%
CELC	44 Neutral	$514.60M	―	-115.39%	―	―	-4.14%
ORIC	43 Neutral	$938.32M	―	-48.45%	―	―	7.15%
ERAS	34 Underperform	$424.93M	―	-45.82%	―	―	10.38%
SANA	33 Underperform	$1.04B	―	-71.44%	―	―	19.94%

Oric Pharmaceuticals Corporate Events

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth

On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.